{"id":"tll-018","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Dehydration"}]},"_chembl":{"chemblId":"CHEMBL5942122","moleculeType":null,"molecularWeight":"536.98"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TLL-018 works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, resulting in reduced blood glucose levels. By targeting SGLT2, TLL-018 provides a novel approach to treating diabetes.","oneSentence":"TLL-018 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:04.317Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06887127","phase":"PHASE3","title":"A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2025-03-10","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT06396026","phase":"PHASE3","title":"A Study of Efficacy and Safety of TLL-018 in CSU Participants","status":"RECRUITING","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2024-12-24","conditions":"Chronic Spontaneous Urticaria","enrollment":436},{"nctId":"NCT05772520","phase":"PHASE2","title":"The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-01-19","conditions":"Plaque Psoriasis","enrollment":82},{"nctId":"NCT05373355","phase":"PHASE1","title":"Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-05-10","conditions":"Chronic Spontaneous Urticaria","enrollment":41},{"nctId":"NCT05945810","phase":"PHASE1","title":"Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-07-12","conditions":"Atopic Dermatitis","enrollment":28},{"nctId":"NCT06020144","phase":"PHASE3","title":"A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs","status":"UNKNOWN","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2023-11-15","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT05342428","phase":"PHASE1","title":"Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-06-10","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":73},{"nctId":"NCT05133297","phase":"PHASE2","title":"The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hangzhou Highlightll Pharmaceutical Co., Ltd","startDate":"2022-02-16","conditions":"Rheumatoid Arthritis","enrollment":101},{"nctId":"NCT05121402","phase":"PHASE2","title":"Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis","status":"WITHDRAWN","sponsor":"TLL Pharmaceutical, LLC","startDate":"2022-12-30","conditions":"Ulcerative Colitis","enrollment":""},{"nctId":"NCT04243083","phase":"PHASE1","title":"A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants","status":"COMPLETED","sponsor":"TLL Pharmaceutical, LLC","startDate":"2020-01-26","conditions":"Healthy","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sequence 1","Sequence 2","Sequence 3","extended-release tablet","TLL-018 tablets"],"phase":"phase_3","status":"active","brandName":"TLL-018","genericName":"TLL-018","companyName":"Hangzhou Highlightll Pharmaceutical Co., Ltd","companyId":"hangzhou-highlightll-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TLL-018 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}